CXCL2 and metastatic malignant neoplasm: Intriguingly, APM‐treated tumor cells in mice exhibited downregulated expression of the chemokine CXCL2, known to contribute to bone osteolysis in metastatic cancer,[22] and downregulation of the CXCL2 production pathway (Figure S5A,D, Supporting Information).